Can two immune boosters outsmart follicular lymphoma without chemo?

NCT ID NCT07731789

Not yet recruiting Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining two lab-made antibodies, tafasitamab and rituximab, can help people with newly diagnosed follicular lymphoma achieve complete remission. Both antibodies are designed to help the immune system recognize and attack cancer cells. The study enrolls 30 adults with grade 1, 2, or 3a follicular lymphoma who need treatment. Researchers will measure how many patients have no signs of cancer after one year and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of two monoclonal antibodies: tafasitamab and rituximab
What this could lead to: If successful, this combination could offer a more effective first-line treatment for follicular lymphoma, potentially leading to higher remission rates without chemotherapy.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from monoclonal antibodies can include infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLASSIC FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLASSIC FOLLICULAR LYMPHOMA GRADE 1 FOLLICULAR LYMPHOMA GRADE 2 FOLLICULAR LYMPHOMA GRADE 3A FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.